Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):February 1, 2005 (January 26, 2005)
GTx, Inc.
Delaware | 005-79588 | 62-1715807 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
3 N. Dunlap Street
Memphis, Tennessee 38163
(901) 523-9700
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
ITEM 8.01 Other Events. | ||||||||
ITEM 9.01 Financial Statements and Exhibits. | ||||||||
SIGNATURE | ||||||||
Ex-99.1 Press Release |
Table of Contents
ITEM 8.01 Other Events.
On January 26, 2005, GTx, Inc. announced that the Company has initiated a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
ITEM 9.01 Financial Statements and Exhibits.
(c) Exhibits
Exhibit | ||||
Number | Description | |||
99.1 | Press Release issued by GTx, Inc. dated January 26, 2005 |
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GTx, Inc. | ||||
Date: February 1, 2005 | By: | /s/ Henry P. Doggrell | ||
Name: | Henry P. Doggrell | |||
Title: | Vice President, General Counsel/Secretary | |||